<- Go Home
Forte Biosciences, Inc.
Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for autoimmune and autoimmune-related diseases. The company offers products, such as its lead product candidate FB102, a proprietary molecule with applications for celiac disease, vitiligo, and alopecia areata; and services, including the clinical development and management of its Phase 2 clinical trials. Forte Biosciences, Inc. was incorporated in 2007 and is based in Dallas, Texas. As of August 27, 2026, Forte Biosciences, Inc. operates as a subsidiary of argenx SE.
Market Cap
$1.9B
Volume
190.5K
Cash and Equivalents
$49.6M
EBITDA
-$94.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$77.20
52 Week Low
$10.11
Dividend
N/A
Price / Book Value
10.24
Price / Earnings
-16.94
Price / Tangible Book Value
10.24
Enterprise Value
$1.7B
Enterprise Value / EBITDA
-18.38
Operating Income
-$94.8M
Return on Equity
62.28%
Return on Assets
-37.79
Cash and Short Term Investments
$198.5M
Debt
N/A
Equity
$183.8M
Revenue
N/A
Unlevered FCF
-$41.3M
Sector
Biotechnology
Category
N/A